ICON (ICLR)
(Delayed Data from NSDQ)
$323.46 USD
+10.36 (3.31%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $326.12 +2.66 (0.82%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$323.46 USD
+10.36 (3.31%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $326.12 +2.66 (0.82%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
Zacks News
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Elevance (ELV) to Divest Life & Disability Business to StanCorp
by Zacks Equity Research
With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.
Hope for Financial Market Stability: Global Week Ahead
by John Blank
Q1-23 has been rattled by bank turmoil. Some financial market stability will be much hoped for in coming days... But don't bet on it.
Here's Why You Should Retain Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens' (WBA) strategic executions on the United States and the international front is likely to have contributed to the Q2 2023 top line.
Icon PLC (ICLR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.29% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Icon PLC (ICLR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Icon PLC (ICLR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.39% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Icon PLC (ICLR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Icon PLC (ICLR) Surges 3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Icon PLC (ICLR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ICLR vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ICLR vs. HQY: Which Stock Is the Better Value Option?
Icon PLC (ICLR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.51% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Icon PLC (ICLR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.85% and 1.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Q4 Earnings Meet Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Icon PLC (ICLR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Icon PLC (ICLR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 4.94% and 1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts (MDRX), CareMetx Tie Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration with CareMetx to streamline specialty medication management for medical clinics and practices across the nation.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
Icon PLC (ICLR) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.